A New Technology that Could Reshape the Vaccine Playing Field

The global distribution of Covid-19 vaccines has been dramatically short of hopes and expectations, but right in line with the warnings from skeptics who know the production constraints from traditional vaccines, which leverage established biotechnology for protein generation. However, there is a new platform driven by an upstart biotech company on the Nasdaq that may […]

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Announces Gregory Naeve As Chief Business Officer

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) reported that the company has appointed Gregory Naeve, Ph.D., as Chief Business Officer. Dr. Naeve will lead portfolio and product strategy and business development for the firm. The details Rick Fair, the CEO and President of Bellicum, reported that they are thrilled to welcome a leader of Dr. Naeve’s caliber and […]

Oncology Remains Pfizer Inc. (NYSE:PFE)’s Strongest Unit

Boston, MA 11/04/2013 (wallstreetpr) – The pharmaceutical giant Pfizer Inc. (NYSE:PFE) released its Q3 data last week, being among the last few in the industry to round off the health care stocks picture after other players having reported earlier. PFE Q3 results topped analysts’ estimates due to its intensive restructuring and cost reduction measures. The company reported […]

Pfizer Inc. (NYSE:PFE) – Strong Portfolio Aid To Growth

Boston, MA 10/22/2013 (wallstreetpr) – Pfizer Inc. (NYSE:PFE), is a research based biopharmaceutical company. They operate in different segments. The company’s diversified portfolio includes animal, human, biologic, vaccine, and small molecule, as well as consumer healthcare and nutritional products. Pfizer’s shareholders have witnessed an appreciation in the share’s value by around 11% which signifies the […]

Civil Lawsuits Against Pfizer Inc. (NYSE:PFE) Moved To The Federal Docket

Boston, MA 10/21/2013 (wallstreetpr) – Separate civil lawsuits that were filed against Pfizer Inc. (NYSE:PFE) in the McDowell County civil court in West Virginia have now been moved to the federal docket in the US District Court for the Southern District of West Virginia and will now be handled there. There were multiple plaintiffs involved in some […]

Pfizer Inc. (NYSE:PFE) Reported Unsatisfactory Results Of Drug For Psoriasis Treatment

Boston, MA 10/18/2013 (wallstreetpr) – A drug tofacitinib which the drug maker Pfizer Inc. (NYSE:PFE) had earlier come up with to treat psoriasis is now seen to demonstrate mixed results in the trials. The company reported that the drug has shown non-inferiority compared to Enbrel in treating psoriasis in adults who were suffering moderately or severely from […]

Pfizer Inc. (NYSE:PFE) Funds Study On Expenditure On Cancer Drugs

Boston, MA 10/15/2013 (wallstreetpr) – According to a research, 126 billion Euros ($171 billion) were spent on cancer drugs in the year 2009. This was established by researchers based in United Kingdom. The research might be helpful to the cancer research officers who might find themselves better equipped with information on cancer and in fighting the […]

Major Drug Makers; Johnson & Johnson (JNJ) and Eli Lilly (LLY) Database Collaboration – JNJ, PFE, BMY, MRK, ABT

On Monday, current three major drug makers Eli Lilly & Co. (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), and Merck & Co., Inc. (NYSE:MRK) have decided to collaborate on a database that will assist speed up the investigational drug testing process. The firm will each contribute to a database, which will be made of doctors, hospitals and […]

Quest Diagnostics (NYSE:DGX) Announce Quarter Dividend and Cost Cut Plan – DGX, DVAX, PFE, JNJ, BMY

Quest Diagnostics Inc (NYSE:DGX) announced on Friday that it is surging its quarterly dividend by 76 percent to 30 cents per share. It will be paid on Jan. 28. The firm reported that it aims to cut costs by $500M in 2014. It will go out 2014 with a run-rate savings of $600M, increase from […]

Titan Pharmaceuticals Falls Through the Floor (TTNP)

Titan Pharmaceuticals (OTC: TTNP) released second quarter results this morning that showed revenues doubling to $1.4 million from the same period in 2011. The top line consisted of royalties on the net sales of Fanapt. Operating expenses in the quarter decreased by 36% from one year ago. For the quarter, the company reported a net of […]

Chromadex Gets A Supplemental Boost From Stock Guru (CDXC)

ChromaDex (OTC: CDXC), a natural products company, has gotten the attention of at least one world-class investor. Dr. Phillip Frost known for his sale of drug maker IVAX to TEVA (NYSE: TEVA) for $7.6 billion in 2005 has been accumulating shares of ChromaDex according to a news story released this afternoon. In June, Frost added […]